- Home
- UPXI vs PBM Comparison
UPXI vs PBM Comparison
Compare UPXI & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- PBM
- Stock Information
- Founded
- UPXI 2018
- PBM 1994
- Country
- UPXI United States
- PBM Canada
- Employees
- UPXI N/A
- PBM N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- PBM
- Sector
- UPXI Health Care
- PBM
- Exchange
- UPXI Nasdaq
- PBM NYSE
- Market Cap
- UPXI 481.8M
- PBM 5.3M
- IPO Year
- UPXI 2021
- PBM N/A
- Fundamental
- Price
- UPXI $10.22
- PBM $3.88
- Analyst Decision
- UPXI
- PBM
- Analyst Count
- UPXI 0
- PBM 0
- Target Price
- UPXI N/A
- PBM N/A
- AVG Volume (30 Days)
- UPXI 6.7M
- PBM 49.3K
- Earning Date
- UPXI 05-20-2025
- PBM 05-20-2025
- Dividend Yield
- UPXI N/A
- PBM N/A
- EPS Growth
- UPXI N/A
- PBM N/A
- EPS
- UPXI N/A
- PBM N/A
- Revenue
- UPXI $18,625,089.00
- PBM N/A
- Revenue This Year
- UPXI $299.03
- PBM N/A
- Revenue Next Year
- UPXI N/A
- PBM N/A
- P/E Ratio
- UPXI N/A
- PBM N/A
- Revenue Growth
- UPXI 4.75
- PBM N/A
- 52 Week Low
- UPXI $1.90
- PBM $0.41
- 52 Week High
- UPXI $22.57
- PBM $824.90
- Technical
- Relative Strength Index (RSI)
- UPXI 55.62
- PBM 44.18
- Support Level
- UPXI $10.69
- PBM $2.99
- Resistance Level
- UPXI $16.00
- PBM $4.80
- Average True Range (ATR)
- UPXI 4.05
- PBM 0.68
- MACD
- UPXI -0.15
- PBM 0.18
- Stochastic Oscillator
- UPXI 16.95
- PBM 47.52
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.